Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of TearLab (NASDAQ: TEAR ) , an ophthalmic (i.e., eye-related) medical device company focused on helping diagnose dry eye disease, dipped as much as 11% after the company reported its third-quarter earnings results.
So what: For the quarter, TearLab reported a whopping 247% increase in revenue to $4.2 million as it received a total of 467 orders for its proprietary TearLab Osmolarity systems for diagnosing dry eye disease. Net loss also shrank modestly to just $4.2 million, or $0.13 per share, from $4.6 million, or $0.17 per share a year ago. Both results were right in line with Wall Street's expectations.
Now what: You might be wondering, "If TearLab's results met expectations, why is it getting pounded today?" I believe the answer lies in witnessing the incredible growth of ophthalmic therapies like Regeneron Pharmaceuticals' Eylea. Investors have observed this and a number of smaller drugs to treat eye diseases prosper over the past year and have been expecting an almost unrealistic ramp-up out of TearLab. Admittedly, I would much rather wait for TearLab to get closer to profitability before even considering jumping on board, but today's move lower appears to be more a fault of investors' frothy hopes and emotions than anything TearLab had to report.
Another revolutionary growth stock you should be watching
TearLab's 247% revenue growth is certainly nothing for investors to gloss over -- but neither is this incredible tech stock, which is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!